In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans (Q39475482)

12 September 2017

In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans (English)

1 reference

12 September 2017

Cryptococcus neoformans

1 reference

6

Jones RN

1 reference

12 September 2017

2

Pfaller MA

1 reference

12 September 2017

Yamazumi T

1

1 reference

12 September 2017

Messer SA

series ordinal

3

1 reference

12 September 2017

Houston A

series ordinal

4

1 reference

12 September 2017

Hollis RJ

series ordinal

5

1 reference

12 September 2017

language of work or name

English

0 references

publication date

1 October 2000

1 reference

Antimicrobial Agents and Chemotherapy

12 September 2017

1 reference

12 September 2017

44

1 reference

12 September 2017

10

1 reference

12 September 2017

2883-2886

1 reference

In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90171

In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90171

In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90171

In vitro activity of a new oral triazole, BMS-207147 (ER-30346)

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90171

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90171

Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90171

In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90171

Multicenter evaluation of broth microdilution method for susceptibility testing of Cryptococcus neoformans against fluconazole

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90171

Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90171

Emergence of cryptococcal disease: epidemiologic perspectives 100 years after its discovery

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90171

New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90171

Molecular subtypes and antifungal susceptibilities of serial Cryptococcus neoformans isolates in human immunodeficiency virus-associated Cryptococcosis. Cryptococcal Disease Active Surveillance Group

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90171

A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90171

The hidden danger of primary fluconazole prophylaxis for patients with AIDS

21 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/10991880

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Synthesis and antifungal activity of novel thiazole-containing triazole antifungals. II. Optically active ER-30346 and its derivatives

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/10991880

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1128/AAC.44.10.2883-2886.2000

1 reference

12 September 2017

1 reference

12 September 2017

PubMed publication ID

10991880

1 reference